Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01647529
Other study ID # R733/17/2010
Secondary ID
Status Completed
Phase N/A
First received July 19, 2012
Last updated November 16, 2015
Start date July 2012
Est. completion date July 2014

Study information

Verified date November 2015
Source Singapore National Eye Centre
Contact n/a
Is FDA regulated No
Health authority SingHealth Centralised Institutional Review Board: Singapore
Study type Interventional

Clinical Trial Summary

Objective of this study is to investigate the intracameral level of ganciclovir following topical application of 0.15% ganciclovir gel (VIRGAN©) for Cytomegalovirus (CMV) anterior uveitis and endothelitis. Thirty patients who are diagnosed with CMV anterior segment infection, either uveitis or endothelitis, who have a positive aqueous real time PCR (RT-PCR) and/or positive tetraplex PCR for CMV and have not had any form of ganciclovir treatment in the past 1 month, will be recruited in the study after taking an informed consent. with active CMV anterior segment infection confirmed by a positive aqueous real time PCR (RT-PCR) and have not had any form of ganciclovir treatment in the past 1 month were recruited in the study. Patients were given 0.15% ganciclovir gel 1cc 5 times a day for 6 weeks. Following 6 weeks of treatment, tears and aqueous samples will be collected. Aqueous will be sent for RT-PCR for CMV status. Ganciclovir drug level in both tears and aqueous will be measured by HPLC method. Clinically, degree of the intraocular inflammation, Intraocular pressure (IOP) and central corneal thickness (CCT) will be recorded at baseline and post-treatment.


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date July 2014
Est. primary completion date July 2013
Accepts healthy volunteers No
Gender Both
Age group 21 Years to 99 Years
Eligibility Inclusion Criteria:

- Age between 21 and above

- Patients who are diagnosed with anterior uveitis or endotheliitis with a positive aqueous real time PCR (RT-PCR) and/or positive tetraplex PCR for Cytomegalovirus (CMV)

- Patients with relapses and recurrent anterior segment disease that is PCR positive for CMV in aqueous

- Have not been on VIRGAN or any other form of ganciclovir therapy for the past 1 month

- Consent to undergo anterior chamber tap and give aqueous and tear samples for the study

- Able to undergo relevant tests (corneal pachymetry and laser flare cell photometry)

- Able to come for subsequent follow-up visits

Exclusion Criteria:

- CMV anterior uveitis with associated retinitis

- Other causes of hypertensive anterior uveitis / endotheliitis such as HSV, VZV infection

- Patients who have been on any form of (topical, local or systemic) ganciclovir therapy for the past1 month.

- Patients who are allergic to ganciclovir

- Patients who will require systemic or intra-vitreal ganciclovir therapy

- Immunocompromised patients

- Positive for HIV, Hep B and Hep C

- Not keen on participating in the study

- Patients who are incapable, either by law or mental state, of giving consents in their own right.

- Patients who are either unable or unwilling to keep scheduled appointments and adhere to the other aspects of the protocol

- Patients who are pregnant or breastfeeding

- Any other specified reason as determined by the clinical investigator.

Study Design

Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Ganciclovir
Treatment with topical ganciclovir ointment

Locations

Country Name City State
Singapore Singapore National Eye Centre Singapore

Sponsors (1)

Lead Sponsor Collaborator
Singapore National Eye Centre

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Median concentration of ganciclovir in anterior chamber and ocular surface Following 6 weeks of continuous application of Virgan gel 0.15% 1cc 5 times a day, the patient will be reviewed at the clinic within 3 hours following the last application of the gel. 6 weeks No
Secondary Correlation of intracameral concentration of virgan with the corneal thickness 6 weeks No
See also
  Status Clinical Trial Phase
Completed NCT00476593 - Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications N/A
Recruiting NCT01486693 - Clinical Outcomes of Topical Ganciclovir Treatment in Cytomegalovirus Anterior Uveitis N/A
Recruiting NCT01156285 - Acute Anterior Uveitis: Psychic Burden and Pain N/A
Terminated NCT00333996 - A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis Phase 2/Phase 3
Completed NCT00405496 - Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis Phase 2
Completed NCT02764697 - Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients Phase 4
Completed NCT01376362 - Topical Interferon Gamma for Macular Edema Secondary to Uveitis Phase 1/Phase 2
Recruiting NCT00407316 - Quality of Life and Visual Function in Uveitis Patients Phase 0
Completed NCT02725177 - Ocular Sarcoidosis Open Label Trial of ACTHAR Gel N/A
Completed NCT00823173 - Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis Phase 2
Completed NCT02517619 - Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis Phase 3
Completed NCT01505088 - Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis Phase 3
Completed NCT02879084 - Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate Uveitis
Completed NCT02765308 - Aqueous Humor Dynamics and Hypertensive Uveitis N/A
Completed NCT01154010 - PEMF: an Adjunct Therapy for Anterior Uveitis N/A
Completed NCT00130637 - Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis Phase 2
Completed NCT00406887 - Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis Phase 3
Completed NCT00876434 - Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveiti Phase 1